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Summary
Reducing obesity requires an elevation of energy expenditure and/or a suppression of food intake. Here we show that
enhancing hepatic glycolysis reduces body weight and adiposity in obese mice. Overexpression of glucokinase or 6-phos-
phofructo-2-kinase/fructose-2,6-bisphosphatase is used to increase hepatic glycolysis. Either of the two treatments pro-
duces similar increases in rates of fatty acid oxidation in extrahepatic tissues, i.e., skeletal muscle, leading to an elevation
of energy expenditure. However, only 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase overexpression causes a
suppression of food intake and a decrease in hypothalamic neuropeptide Y expression, contributing to a more pronounced
reduction of body weight with this treatment. Furthermore, the two treatments cause differential lipid profiles due to
opposite effects on hepatic lipogenesis, associated with distinct phosphorylation states of carbohydrate response element
binding protein and AMP-activated protein kinase. The step at which hepatic glycolysis is enhanced dramatically influ-
ences overall whole-body energy balance and lipid profiles.Introduction
Obesity is highly associated with type 2 diabetes and causes
or exacerbates many health problems (Reaven, 1995). The
mechanism for the pathogenesis of obesity remains unclear
but in general terms is due to a loss of balance between energy
intake (feeding) and energy expenditure (Spiegelman and Flier,
2001). Thus, obesity develops when energy intake chronically
exceeds total body energy expenditure. Dysregulation of en-
ergy expenditure, at least in part, is attributable to impaired
glucose and lipid metabolism. Notably, hyperinsulinemia, in
combination with hyperglycemia, inhibits fatty acid oxidation
in many tissues (Bavenholm et al., 2000; Chien et al., 2000;
Rasmussen et al., 2002; Sidossis and Wolfe, 1996). As a result,
lipogenesis is favored over fatty acid oxidation (Ruderman et
al., 2003), leading to an increase in fat accumulation and a de-
crease in energy expenditure. Food intake, as the other com-
ponent of energy balance, is controlled by the central nervous
system (CNS), where the hypothalamus plays the most impor-
tant role (Havel, 2001; Spiegelman and Flier, 2001). In hypothal-
amus, the arcuate nucleus (ARC) contains neurons expressing
neuropeptide Y (NPY) and agouti-related protein (AgRP), which
increase food intake, and neurons expressing pro-opiomelano-
cortin (POMC) and cocaine-amphetamine-related transcript
(CART), which suppress food intake (Friedman, 2004). In ge-
netic obese mice, hypothalamic NPY and/or AgRP mRNAs are
elevated (Ollmann et al., 1997; Wilding et al., 1993). These
changes are likely associated with increased food consump-
tion (Williams et al., 2000).
One approach to reduce obesity is to elevate energy expen-
diture. In mice lacking acetyl-CoA carboxylase 2 (ACC2) (Abu-
Elheiga et al., 2001), stearoyl-CoA desaturase-1 (SCD1) (CohenCELL METABOLISM : AUGUST 2005 · VOL. 2 · COPYRIGHT © 2005 ELSet al., 2002), or mice transgenic-expressing fibroblast growth
factor-19 (FGF19) (Tomlinson et al., 2002), fatty acid oxidation
is increased and whole-body energy expenditure is elevated.
Consequently, fat mass and body weight are reduced or the
development of obesity is prevented. In these studies, reduc-
tion of obesity involves a number of tissues, including liver,
muscle, and brown adipose tissue, which cooperatively regu-
late whole-body fuel utilization. However, the relative role of
individual tissues in the determination of whole-body energy
expenditure is not well-defined. In addition, the above studies
demonstrate that elevating fatty acid oxidation can improve
glucose homeostasis. How enhancing glucose utilization af-
fects lipid metabolism in terms of regulation of energy balance
in obesity is not clear. Another approach for reduction of obe-
sity is to suppress food intake. This is exemplified by peripheral
administration of glucagon-like peptide-1 (GLP-1) derivative,
NN2211, which reduces food intake and body weight in obese
rats (Larsen et al., 2001). Since GLP-1 acts through binding to
GLP-1 receptor in the CNS (Baggio et al., 2004), this study
suggests that effects on the CNS are associated with a reduc-
tion of obesity through suppression of food intake.
Since insulin, in combination with glucose, is a major signal
that regulates peripheral fatty acid oxidation (Bavenholm et al.,
2000; Chien et al., 2000; Rasmussen et al., 2002; Sidossis and
Wolfe, 1996), we hypothesized that lowering plasma insulin
levels should be able to elevate energy expenditure and reduce
obesity. Lowering plasma insulin levels can be achieved by re-
ducing plasma glucose levels via suppression of hepatic glucose
production (HGP). In the liver, glucokinase (GK) and 6-phospho-
fructo-2-kinase/fructose-2,6-bisphosphatase (6PFK2/FBP2) are
the two crucial enzymes that control glycolytic flux (Nordlie et
al., 1999; Wu et al., 2005). GK catalyzes glucose phosphoryla-EVIER INC. DOI 10.1016/j.cmet.2005.07.003 131
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FBP2 (dephosphorylated hepatic isoform) elevates fructose-
2,6-bisphosphate (F26P2) to activate 6-phosphofructo-1-kinase
(6PFK1) and promotes the step in glycolysis from fructose-6-
phosphate (F6P) to fructose-1,6-bisphosphate (F16P2). Thus,
we chose to overexpress GK or 6PFK2/FBP2 in the liver of
obese mice to explore the role of liver, particularly hepatic gly-
colysis, in the regulation of energy balance and obesity. In the
course of these studies, we found dramatically different out-
comes depending on the site of glycolysis targeted.
Results
Enhancement of hepatic glycolysis
In order to enhance hepatic glycolysis, Ad-GK or Ad-Bif-BPD
were introduced into obese KK/H1J mice, a polygenic model
of obesity and type 2 diabetes (Bouchard et al., 2002; Igel et
al., 1998; Koishi et al., 2002; Nagase et al., 1996). Seven days
after viral infusion, overexpression of either enzyme in livers of
the treated mice was evident (Figure 1A). These manipulations
caused a similar increase in hepatic glycolysis, which was evi-
denced by elevated levels of hepatic lactate (Table 1). In addi-
tion, whole-body glycolysis, measured during euglycemic/
hyperinsulinemic clamp, was also increased similarly in Ad-
GK- or Ad-Bif-BPD-treated mice (Figure 1B). Because adenovi-
ral overexpression predominantly targets the liver (Becard et
al., 2001; O’Doherty et al., 1999), enhanced glycolysis likelyFigure 1. Enhancing hepatic glycolysis regulates whole-body glucose homeostasis
Obese KK/H1J mice were treated with adenovirus (Ad-GFP, Ad-GK, or Ad-Bif-BPD) on day 0 and followed for 7 days.
A) Hepatic overexpression of GK or 6PFK2/FBP2. In (B), (C), and (D), data are means ± SE, n = 4–6. **p < 0.01 or ***p < 0.001 versus Ad-GFP.
B) Glycolysis.
C) Basal and insulin-suppressed hepatic glucose production (HGP).
D) Basal and insulin-stimulated whole-body glucose disposal (Rd).132occurred predominantly in the liver. This view was substan-
tiated by the exclusive hepatic localization, in vivo, of green
fluorescent protein (GFP) in the Ad-GFP-treated mice in the
present study (data not shown). Upon enhancing hepatic gly-
colysis, both basal and insulin-suppressed HGP were de-
creased in Ad-GK- or Ad-Bif-BPD-treated mice compared to
those of Ad-GFP-treated mice (Figure 1C). Whole-body glu-
cose disposal, calculated as the rate of glucose disappearance
(Rd), was decreased under the basal condition but increased
under the hyperinsulinemic condition in Ad-GK- or Ad-Bif-
BPD-treated mice (Figure 1D).
Reduction of body weight and adiposity
Upon enhancing hepatic glycolysis, Ad-GK- or Ad-Bif-BPD-
treated KK/H1J mice showed reductions in body weight and
adiposity, compared to Ad-GFP-treated mice (Figures 2A and
2B). Interestingly, Ad-Bif-BPD treatment produced much greater
effects on reducing body weight than Ad-GK treatment. Since
Ad-Bif-BPD treatment also suppressed food intake (see be-
low), a group of Ad-GFP-treated mice were pair fed (Ad-GFP-
PF) with mice treated with Ad-Bif-BPD. Food restriction caused
a reduction of body weight and adiposity, but this effect was
not as pronounced as that caused by Ad-Bif-BPD treatment
(Figures 2A and 2B). Hence, the suppression of food intake
only contributes partially to effects of Ad-Bif-BPD treatment on
body weight loss.CELL METABOLISM : AUGUST 2005
Enhancing hepatic glycolysis reduces obesityTable 1. Changes in levels of hepatic metabolites and plasma parameters
Ad-GFP Ad-GK Ad-Bif-BPD
Hepatic metabolites
Lactate (mole/g) 6.23 ± 1.14 11.64 ± 1.39* 9.49 ± 0.83*
Triglycerides (mg/g) 20.12 ± 1.60 79.19 ± 3.04*** 18.05 ± 3.72‡‡‡
G6P (mole/g) 0.65 ± 0.19 0.93 ± 0.02*** 0.70 ± 0.01‡‡‡
F6P (mole/g) 0.19 ± 0.01 0.26 ± 0.02** 0.23 ± 0.02
Xu5P (nmole/g) 57.13 ± 7.45 87.29 ± 10.43** 41.26 ± 5.11‡‡
Plasma parameters
ALT (IU) 31.96 ± 4.78 38.23 ± 3.78 28.71 ± 7.06
AST (IU) 37.43 ± 4.33 31.06 ± 5.62 32.56 ± 4.09
Glucose (mg/dl)
b 283.16 ± 43.13 153.87 ± 10.32* 148.47 ± 9.41*
a 218.36 ± 12.94 117.15 ± 15.89** 115.45 ± 9.05**
Triglycerides (mM) 2.11 ± 0.10 6.45 ± 1.71* 1.74 ± 0.10*,‡
Free fatty acids (mM) 2.04 ± 0.25 3.30 ± 0.67* 2.05 ± 0.48‡
Insulin (ng/ml) 9.70 ± 1.24 4.57 ± 0.23* 4.43 ± 0.22*
Leptin (ng/ml) 13.30 ± 0.83 0.33 ± 0.40*** 9.10 ± 1.47*,‡‡
Obese KK/H1J mice were treated with adenoviruses on day 0 and followed for 7 days. Hepatic metabolites were measured from frozen tissues that were collected on
day 7 after 5 hr RQ experiment (5 hr fasting). Plasma glucose was monitored before (b) and after (a) RQ experiment. Other plasma parameters were measured only
after RQ experiment. Data are means ± SE, n = 5–8. *p < 0.05, **p < 0.01, or ***p < 0.001 versus Ad-GFP; and ‡p < 0.05, ‡‡p < 0.01, or ‡‡‡p < 0.001 versus Ad-GK.contribution to an increase in whole-body fatty acid oxidation.mice (Figure 3B). The effects of Ad-GK treatment on energy
Figure 2. Enhancing hepatic glycolysis reduces body weight and adiposity
Obese KK/H1J mice were treated with adenovirus (Ad-GFP, Ad-GK, or Ad-Bif-BPD) on day 0 and followed for 7 days. A group of mice (Ad-GFP-PF) was treated with
Ad-GFP and pair fed with Ad-Bif-BPD-treated mice. Data are means ± SE, n = 5–8. *p < 0.05 or **p < 0.01 versus Ad-GFP, †p < 0.05 or ††p < 0.01 versus Ad-GFP-PF,
and ‡p < 0.05 or ‡‡p < 0.01 versus Ad-GK.
A) Body weight was monitored daily.
B) Epididymal, perinephric, and mesenteric fat depots were dissected and weighed as visceral fat content on day 7.Elevation of whole-body energy expenditure
To test whether enhancing hepatic glycolysis leads to an in-
crease in whole-body energy expenditure, the respiratory quo-
tient (RQ) of virus-treated mice was measured on day 7. Ad-
GK and Ad-Bif-BPD treatments caused identical reductions of
RQ values compared to mice treated with control virus, Ad-
GFP (Figure 3A). Food restriction did not change RQ values in
the pair-fed mice. It should be noted that RQ values were lower
in both Ad-GK- and Ad-Bif-BPD-treated mice than in Ad-GFP-
treated mice at the initial time points. Moreover, RQ values
were further reduced late in the 4 hr measurement when the mice
were becoming fasted, compared to Ad-GFP-treated mice.
Energy expenditure, calculated from RQ data (Baar et al.,
2004; Chen and Heiman, 2001), was elevated in both Ad-GK-
and Ad-Bif-BPD-treated mice compared to Ad-GFP-treatedCELL METABOLISM : AUGUST 2005expenditure were greater than Ad-Bif-BPD treatment. In con-
trast, the pair-fed mice (Ad-GFP-PF) showed similar energy ex-
penditure compared to Ad-GFP-treated mice, indicating that
restriction of food intake does not affect whole-body fatty acid
oxidation. There were no differences in the motion index of any
treated mice, indicating that physical activities of all groups of
treated mice were similar (data not shown).
We next measured palmitate oxidation rates of the liver and
skeletal muscle to determine the contribution of individual tis-
sues to the elevated whole-body fatty acid oxidation. Treatment
with either Ad-GK or Ad-Bif-BPD caused a dramatic increase
in the rates of palmitate oxidation in skeletal muscle (Figure
3C). In contrast, both treatments slightly decreased the rates
of palmitate oxidation in liver. These data suggested that extra-
hepatic tissues, including skeletal muscle, made a dominant133
A R T I C L EFigure 3. Enhancing hepatic glycolysis elevates energy expenditure
Obese KK/H1J mice were treated with adenovirus (Ad-GFP, Ad-GK, or Ad-Bif-BPD) on day 0 and followed for 7 days. A group of mice (Ad-GFP-PF) was treated with
Ad-GFP and pair fed with Ad-Bif-BPD-treated mice. Data are means ± SE, n = 5–8. *p < 0.05, **p < 0.01, or ***p < 0.001versus Ad-GFP; †p < 0.05 or ††p < 0.01 versus
Ad-GFP-PF; and ‡p < 0.05 versus Ad-GK.
A) RQ was measured on day 7 using indirect calorimetry.
B) Energy expenditure was calculated from RQ data.
C) Changes in the rates of palmitate oxidation. Results were expressed as the percentage of liver or muscle control.Reduction of plasma levels of glucose and insulin
Enhancing hepatic glycolysis caused a suppression of HGP.
This effect was thought to be responsible for lowering plasma
glucose levels, which were observed with either Ad-GK or Ad-
Bif-BPD treatment (Table 1). Due to these lower levels, glu-
cose-stimulated insulin release (GSIR) is decreased in the pan-
creatic β cells, resulting in a subsequent reduction of plasma
levels of insulin. Moreover, reductions of plasma levels of glu-
cose and insulin were identical in the two liver-targeted manip-
ulations. Initially, we used the decrease in plasma glucose and
subsequent decrease in insulin levels as a simple explanation
for the observed effects on promoting fatty acid oxidation in
extrahepatic tissues. However, the dramatic differences in many
aspects produced by the treatments strongly indicate that re-
ducing obesity by enhancing hepatic glycolysis is a compli-
cated process involving additional mechanisms.
Differential effects on food intake
Food intake is one of two determinants of energy balance. We
monitored food intake of virus-treated mice daily. Ad-Bif-BPD
treatment caused a suppression of food intake compared to
Ad-GFP treatment, whereas Ad-GK treatment did not (Figure
4A). Thus, enhancing hepatic glycolysis at the step from glu-
cose to G6P or from F6P to F16P affects feeding behavior2
134differently. Because food intake is controlled by the CNS
through integration of hormonal and nutritional signals (Flier,
2004; Havel, 2001), we next measured changes in mRNA levels
of neuropeptides that control feeding behavior. Upon Ad-Bif-
BPD treatment, the mRNA levels of hypothalamic NPY were
decreased, suggesting that the CNS is secondarily affected.
However, Ad-GK treatment did not affect NPY mRNA levels
(Figure 4B).
Insulin may cooperate with leptin in the CNS signaling path-
way for regulation of food intake (Flier, 2004; Havel, 2001; Spie-
gelman and Flier, 2001). Because plasma insulin levels were
decreased similarly in both Ad-GK- and Ad-Bif-BPD-treated
mice, we measured levels of plasma leptin. In the Ad-GFP-
treated obese mice, plasma leptin levels were high. Upon Ad-
Bif-BPD treatment, plasma leptin levels were moderately de-
creased (Table 1). Ad-GK treatment, surprisingly, produced a
dramatic decrease in leptin levels. This decrease, however, was
not accompanied by a change in food intake.
Differential effects on lipid metabolism
Although Ad-GK or Ad-Bif-BPD treatment produced identical
effects on lowering plasma glucose and insulin levels, the two
treatments caused strikingly different profiles of lipid metabo-
lism. Upon Ad-GK treatment, the liver showed a 2- to 3-foldCELL METABOLISM : AUGUST 2005
Enhancing hepatic glycolysis reduces obesityFigure 4. Enhancing hepatic glycolysis affects food intake and mRNAs of hypothalamic neuropeptides
Obese KK/H1J mice were treated with adenovirus (Ad-GFP, Ad-GK, or Ad-Bif-BPD) on day 0 and followed for 7 days. Data are means ± SE. *p < 0.05 or **p < 0.01
versus Ad-GFP and ‡p < 0.05 or ‡‡p < 0.01 versus Ad-GK.
A) Cumulative food intake (n = 5–8). A group of mice (Ad-GFP-PF) was treated with Ad-GFP and pair fed with Ad-Bif-BPD-treated mice. The line indicating changes in
food intake of Ad-GFP-PF-treated mice was superimposable on that of Ad-Bif-BPD-treated mice due to pair feeding.
B) Changes in mRNA levels of hypothalamic AgRP, NPY, CART, and POMC (n = 3). The mRNA levels were determined by real-time PCR.increase in the size and a distinct pale-to-white color that was
different from that of mice in all other groups (Figure 5A). These
changes were consistent with 4-fold increases in hepatic tri-
glycerides (TG, Table 1). Ad-Bif-BPD treatment, in contrast, did
not change the weight or appearance of liver and did not influ-
ence hepatic TG levels. In addition, Ad-GK treatment ex-
acerbated the existing hyperlipidemia in the KK/H1J mice, ele-
vating plasma levels of triglycerides (TG) by 3-fold, whereas
Ad-Bif-BPD treatment decreased plasma TG levels (Table
1). To test whether hepatic lipogenesis was responsible for
changes in the lipid profile, we measured the in vivo rates of
lipogenesis in liver. As expected, Ad-GK treatment caused a
significant increase in hepatic lipogenesis. However, Ad-Bif-
BPD treatment caused a decrease in hepatic lipogenesis (Fig-
ure 5B). Similar effects were also observed in rat primary hepa-
tocytes (Figure 5B), indicating that the outcome of elevating
glycolysis on lipogenesis is dramatically different depending on
which step of glycolysis is targeted.
To understand the underlying mechanism, we measured
changes in mRNA levels of lipogenic enzymes, acetyl CoA car-
boxylase 1 (ACC1), and fatty acid synthase (FAS). In the liver,
ACC1 and FAS mRNA levels were increased in Ad-GK-treated
mice, whereas they were decreased in Ad-Bif-BPD-treated
mice (Figure 5C). Similar effects have been observed in Ad-
GK- or Ad-Bif-BPD-treated normal 129J mice (J.E.K., C.W.,
C.J.H., B. Clem, and A.J.L., unpublished data). Unlike changes
in the liver, ACC1 and FAS mRNA levels were decreased in
skeletal muscle upon Ad-GK or Ad-Bif-BPD treatment (Fig-
ure 5D).
Transcription factor carbohydrate response element binding
protein (ChREBP) is thought to mediate effects of glucose on
induction of gene expression of lipogenic enzymes in the liver
(Stoeckman and Towle, 2002; Uyeda et al., 2002). Since he-
patic ChREBP mRNA levels were decreased with either Ad-
GK or Ad-Bif-BPD treatment (data not shown), we measured
changes in ChREBP protein amount and phosphorylation
state. In all virus-treated mice, ChREBP protein amounts were
nearly the same. However, phosphorylation of ChREBP wasCELL METABOLISM : AUGUST 2005dramatically decreased in the liver of Ad-GK-treated mice and
was not significantly changed in the liver of Ad-Bif-BPD-
treated mice (Figure 5E). The decreased phosphorylation of
ChREBP was likely associated with an elevation of hepatic
levels of xylulose-5-phosphate (Xu5P), a regulatory metabolite
(see below).
Since AMP-activated protein kinase (AMPK) plays an impor-
tant role in regulation of lipid synthesis in the liver, we also
measured changes in protein amount and phosphorylation
state of AMPK. In the liver of Ad-GK-treated mice, protein
amount and phosphorylation of AMPK were dramatically de-
creased (Figure 5E). These decreases were not observed with
Ad-Bif-BPD treatment. Instead, AMPK phosphorylation was in-
creased. Clearly, enhancing hepatic glycolysis at two distinct
steps resulted in opposite effects on AMPK expression and
phosphorylation.
Differential effects on hepatic G6P and Xu5P levels
Hepatic levels of G6P and Xu5P are closely associated with
lipid metabolism in the liver (Kabashima et al., 2003; Towle et
al., 1997). Thus, we measured changes in their levels (Table 1).
With Ad-GK treatment, the hepatic levels of both G6P and
Xu5P were increased (0.93 ± 0.03 mol/g and 87.29 ± 10.43
nmol/g, respectively) compared to those of mice treated with
Ad-GFP (0.65 ± 0.19 mol/g and 57.13 ± 7.45 nmol/g, respec-
tively). The increases in G6P were consistent with the effects
of GK on phosphorylation of glucose, while the increases in
Xu5P were likely associated with increased flux through pen-
tose phosphate pathway due to the elevation of G6P (Kaba-
shima et al., 2003). However, with Ad-Bif-BPD treatment, the
hepatic levels of the two metabolites were not significantly
changed.
Discussion
Increasing peripheral fatty acid oxidation can elevate energy
expenditure and lead to a reduction or a prevention of obesity
(Abu-Elheiga et al., 2001; Cohen et al., 2002; Tomlinson et al.,135
A R T I C L EFigure 5. Enhancing hepatic glycolysis alters lipid metabolism
A) Changes of liver appearance. Livers from Ad-Bif-BPD-, Ad-GFP-, or Ad-GK-treated mice (from left to right) were collected on day 7. The dark bar is at a length of
1 cm. In (B), (C), and (D), data are means ± SE. *p < 0.05, **p < 0.01, or ***p < 0.001 versus Ad-GFP, and ‡‡‡p < 0.001 versus Ad-GK.
B) Changes in lipogenesis. Top, in vivo lipogenesis in the liver (n = 3–4); bottom, lipogenesis in rat primary hepatocytes (measured from three to four independent experi-
ments).
C) Changes in mRNA levels of ACC1 and FAS in the liver (n = 5–8).
D) Changes in mRNA levels of ACC1 and FAS in skeletal muscle (n = 5–8).
E) Changes in protein amount and phosphorylation of ChREBP and AMPK in the liver. Phospho-ChREBP was analyzed from immunoprecipitation complex using
phospho-protein gel stain.2002). Because insulin, along with glucose, controls peripheral
fatty acid oxidation and plasma levels of glucose, and because
insulin can be manipulated secondarily via modulation of HGP,
we used adenoviral overexpression of GK or a mutated form
of 6PFK2/FBP2 to test whether and how enhancing hepatic
glycolysis reduces obesity. Using these two manipulations, we
were able to enhance glycolysis predominantly in the liver. Sig-
nificantly, both of these manipulations resulted in identical glu-
cose and insulin lowering effects. Because of this, we were
able to dissect hepatic glycolysis at different steps and explore
the role of each in the regulation of whole-body energy bal-
ance. These novel studies highlight both the central role of the
liver in systemic energy balance and the mechanisms for dif-
ferential regulation of hepatic lipogenesis.
Upon hepatic overexpression of either GK or 6PFK2/FBP2,136glycolysis was increased similarly in the liver, as indicated by
elevated hepatic lactate levels. In addition, the rates of in vivo
glycolysis were also increased similarly. These effects led to a
similar decrease in HGP, which resulted in a similar reduction
of levels of plasma glucose and, secondarily, a similar reduc-
tion of levels of plasma insulin. As a result, there was a relief
of the inhibition of hyperinsulinemia on lipolysis in adipose tis-
sue and fatty acid oxidation in muscle (Chien et al., 2000; Ras-
mussen et al., 2002; Sidossis and Wolfe, 1996; Stumvoll et al.,
2000). In addition, when HGP was decreased, whole-body glu-
cose disposal was also reduced, indicating a decrease in glu-
cose utilization in peripheral tissues, i.e., muscle. From this
perspective, an increase in fat utilization in muscle was ex-
pected to compensate for a reduction of glucose as a fuel.
This change was reflected by decreases in the RQ values. AsCELL METABOLISM : AUGUST 2005
Enhancing hepatic glycolysis reduces obesityexpected, visceral fat content was decreased and the rates of
fatty acid oxidation in skeletal muscle were increased in the
treated mice, which contributed to the elevation of energy ex-
penditure. Since the observed effects were nearly identical with
GK or 6PFK2/FBP2 overexpression, the underlying mecha-
nism(s) is likely the same. Therefore, reducing hyperinsulinemia
secondary to lowering hyperglycemia by enhancing hepatic
glycolysis may be the main contributor to an elevation of en-
ergy expenditure. This mechanism suggests that lowering
plasma glucose levels likely mediates the liver-initiated intertis-
sue interaction with extrahepatic tissues, such as pancreatic β
cells, adipose, and skeletal muscle.
When energy expenditure was similarly elevated, a similar
reduction of obesity was also expected. However, this was not
the case. 6PFK2/FBP2 overexpression caused a more pro-
nounced effect on reduction of body weight than did GK over-
expression. This difference was attributable to differential ef-
fects of the two treatments on food intake. 6PFK2/FBP2
overexpression led to a suppression of food intake that was
not observed with GK overexpression. When energy expendi-
ture is elevated, food intake is usually increased due to
counterregulation, which contributes to decreased effec-
tiveness in reduction of obesity (Jequier, 2002; Perseghin,
2001). In this regard, enhancing hepatic glycolysis at the step
from F6P to F16P2 promoted cooperative regulation of energy
balance to reduce obesity. Since food intake is controlled by
the CNS (Flier, 2004; Havel, 2001), it is likely that 6PFK2/FBP2
overexpression led to secondary effects on the CNS. This view
was supported by a decrease in hypothalamic NPY mRNA
levels. With adenoviral overexpression, the initial alterations
occurred in the liver (Becard et al., 2001; O’Doherty et al.,
1999). Thus, liver-derived signals, neuronal, hormonal, or meta-
bolic, might contribute to observed effects on food intake or
hypothalamic NPY mRNA levels. In addition, the generation of
liver-derived signals was likely determined by how hepatic gly-
colysis is enhanced. In the liver, AMPK, a key cellular energy
sensor (Kahn et al., 2005), showed increased phosphorylation
upon 6PFK2/FBP2 overexpression. Thus, it might serve as one
of the signals to trigger an unknown hepatic neuronal sensor
(or sensors) that is (are) connected with the CNS. Alternatively,
6PFK2/FBP2 overexpression might generate liver-derived sig-
nals, i.e., unknown protein(s), which would be secreted into the
bloodstream and affect the CNS.
TG and leptin similarly may serve as circulating signals that
impact the CNS. In fact, plasma TG levels correlated positively
with NPY mRNA levels in all virus-treated mice. Leptin levels
did not but the ratios of leptin to insulin did correlate negatively
with NPY mRNA levels (data not shown). These correlations
were consistent with the observed effects on food intake. In
addition, leptin may cooperate with insulin on affecting the
CNS. Since insulin stimulates leptin gene expression (Havel,
2001), a reduction of plasma insulin levels was expected to
cause a decrease in plasma levels of leptin. This decrease was
observed with either GK or 6PFK2/FBP2 overexpression. How-
ever, the two treatments also caused dramatic differences in
leptin levels even though insulin levels were the same. These
differences suggested that an additional factor (or factors) is
involved in the regulation of leptin expression. Regardless of
the mechanism (or mechanisms) for reduction of food intake,
decreases in hypothalamic NPY mRNA levels serve as evi-
dence of the existence of intertissue communication from theCELL METABOLISM : AUGUST 2005liver to the brain, functioning as an additional component of
the brain-liver circuit as proposed by Rossetti and colleagues
(Pocai et al., 2005). It should be pointed out that we can not
completely rule out the possibility that there may be a small
amount of infection of the CNS by adenovirus treatment. Even
if this is the case, it is likely that GK and 6PFK2/FBP2 overex-
pression generate different central signals for regulation of
feeding.
Given the fact that GK or 6PFK2/FBP2 overexpression
caused similar changes in rates of glycolysis but different con-
sequences on the lipid profile and reduction of obesity, it is
clear that the site at which glycolysis is enhanced in the liver
can influence the outcome of whole-body lipid metabolism, as
well as whole-body energy balance. This is particularly true
with regard to the correlation between plasma TG levels and
hypothalamic NPY mRNA levels. Since plasma TG levels were
closely associated with hepatic lipogenesis, how lipogenesis
was regulated in the liver was the key. Here, the opposite ef-
fects on ACC1 and FAS mRNAs contributed to differential reg-
ulation of hepatic lipogenesis. In light of the fact that gene ex-
pression of ACC1 and FAS is regulated by ChREBP and
dephosphorylation of ChREBP is controlled by Xu5P-activated
PP2A (Kabashima et al., 2003), a model for the underlying
mechanism(s) was proposed. In this model, GK overexpression
caused an increase in Xu5P levels through the pentose phos-
phate pathway. This increase activated PP2A, which led to an
activation of ChREBP by removal of inhibitory phosphate(s). As
a result, expression of ACC1 and FAS was increased. In addi-
tion, NADPH, another key product of the pentose phosphate
pathway required for lipogenesis, was also likely increased to
promote lipogenesis. None of these changes occurred upon
6PFK2/FBP2 overexpression. Instead, levels of G6P, Xu5P, and
ChREBP phosphorylation were changed in a pattern favoring
a decrease in lipogenesis, consistent with the proposed model.
AMPK also controls lipid synthesis in the liver. Activation of
AMPK by phosphorylation inhibits ACC1 (Kahn et al., 2005).
In addition, phosphorylation of AMPK inhibits the binding of
ChREBP to DNA, which is required for induction of expression
of genes for lipogenic enzymes (Kawaguchi et al., 2002). Upon
enhancing glycolysis via GK overexpression, hepatic AMPK
was dramatically decreased in both protein amount and phos-
phorylation. These changes are expected to cause a decrease
in inhibition of ACC1 and an increase in the binding of ChREBP
to DNA. As a result, lipid synthesis would be favored in the
liver, which is what was observed. Upon enhancing hepatic
glycolysis via 6PFK2/FBP2 overexpression, the increased
phosphorylation of hepatic AMPK and decreased mRNAs of
ACC1 and FAS were consistent with the AMPK-related mecha-
nisms for a repression of lipid synthesis. How these opposite
effects on hepatic AMPK were produced was not clear.
In conclusion, the liver plays an important role in the regula-
tion of energy balance, and this is demonstrated by the reduc-
tion of obesity brought about by enhancing hepatic glycolysis.
In addition, how hepatic glycolysis is enhanced determines the
overall outcome of whole-body energy balance, evidenced by
the fact that GK or 6PFK2/FBP2 overexpression caused dif-
ferential effects on reduction of body weight and changes of
lipid profiles in obese mice. When hepatic glycolysis is en-
hanced at the downstream step, energy balance is coopera-
tively regulated via the intertissue interactions between the liver
and extrahepatic tissues. Through suppression of HGP, en-137
A R T I C L Ehancing hepatic glycolysis at the step from F6P to F16P2 leads
to a decrease in plasma insulin levels secondary to a reduction
of plasma glucose levels, which in turn promotes fatty acid
oxidation in extrahepatic tissues, i.e., skeletal muscle, and ele-
vates whole-body energy expenditure. In addition, unknown
liver-derived signal (or signals) is likely generated uniquely in
response to enhancing hepatic glycolysis at the downstream
step and secondarily affects the hypothalamus, contributing to
a suppression of food intake. The mechanistic scheme is sum-
marized in Figure 6, showing how GK and 6PFK2/FBP2 over-
expression regulates energy balance differently.
Experimental procedures
Adenovirus preparation
Adenoviruses encoding green fluorescent protein (Ad-GFP), glucokinase
(Ad-GK), and bisphosphatase-deficient 6PFK2/FBP2 (Ad-Bif-BPD) were
prepared as previously described (O’Doherty et al., 1999; Wu et al., 2001,
2004). The expressed bisphosphatase-deficient 6PFK2/FBP2, possessing
a serine-32 to alanine mutation and a histidine-258 to alanine mutation, was
designed to generate a higher level of F26P2 compared to wild-type
enzyme.
Animal treatments
Male obese KK/H1J mice were 12–14 weeks old (w35 g) and obtained from
the Jackson Laboratory (Bar Harbor, Maine). All mice were fed ad libitum
and individually housed and maintained on a 12:12 hr light-dark cycle, with
lights turned on at 06:00. Adenovirus (Ad-GFP, Ad-GK, or Ad-Bif-BPD) was
administered at 17:00 of day 0 via tail vein at a dose of w5 × 1011 pfu/ml ×
0.45 ml. Body and food weight were measured daily at 10:00 on day −2
through day 7. The pair-fed mice (treated with Ad-GFP) were provided with
the same amount of food as voluntarily ingested the previous day by Ad-
Bif-BPD-treated mice at 17:00 on day −2 through day 7. At day 7, one setFigure 6. The mechanistic scheme for regulation of
energy balance by enhancing hepatic glycolysis
Enhancing hepatic glycolysis via GK or 6PFK2/
FBP2 overexpression causes an elevation of energy
expenditure, likely through effects secondary to
lowering plasma insulin and glucose levels. How-
ever, the two modulations cause opposite conse-
quences on lipid profiles as well as differences in
food intake. On the right side, when hepatic glycoly-
sis is enhanced at the step from glucose to glucose-
6-phosphate, hepatic lipogenesis is increased. On
the left side, when hepatic glycolysis is enhanced at
the step from fructose-6-phosphate to fructose-1,6-
bisphosphate, food intake is suppressed and he-
patic lipogenesis is decreased. Thus, when glycoly-
sis is enhanced at the downstream step, the liver
plays an important role in cooperative regulation of
energy balance to reduce obesity.138of mice comprised of those treated with Ad-GFP, Ad-GK, Ad-Bif-BPD, and
Ad-GPF-PF (n = 5–8) were used for RQ measurements. After RQ experi-
ments, blood samples were collected from the tail vein, and mice were
immediately sacrificed via cervical dislocation. The abdomen was quickly
opened. Epididymal, perinephric, and mesenteric fat depots were dissected
and weighed as visceral fat content (Barzilai et al., 1999). After weighing,
the liver and skeletal muscle were rapidly trimmed and divided into two
parts. One part of each tissue was frozen in liquid nitrogen and subse-
quently stored at −70°C for further analyses. The second part of the liver
or skeletal muscle sample was immediately cooled in ice-cold buffer and
homogenized. Tissue homogenates were used for determination of fatty
acid oxidation as described below. The hypothalamic regions were dis-
sected from 1 mm thick sagittal sections of fresh brain (Minokoshi et al.,
2004). The arcuate nucleus (ARC), paraventricular (PVN), ventromedial
(VMH), and dorsomedial (DMH) were collected microscopically, rapidly
trimmed and frozen in liquid nitrogen, and subsequently stored at −70°C
for further analyses. Two additional sets of mice treated with Ad-GFP, Ad-
GK, and Ad-Bif-BPD (n = 4–6) were used separately for euglycemic/hyperin-
sulinemic studies and measurement of in vivo lipogenesis. All study proto-
cols were reviewed and approved by the Institutional Animal Care and Use
Committees of the University of Minnesota.
Primary hepatocyte preparation and treatment
Primary hepatocytes were isolated from SD rats as previously described
(Stoeckman and Towle, 2002). Hepatocytes were plated into 12-well plates
(w7 × 105 cells/well) for 4 hr with Williams E media. After overnight incuba-
tion, cells were treated with Ad-GFP, Ad-GK, or Ad-Bif-BPD (3.5 × 107 pfu/
well) for 2 hr in Williams E media without FBS or insulin. Cells were then
washed with PBS and incubated in Williams E media without FBS or insu-
lin overnight.
RQ measurement
Respiratory gas measurements were taken by indirect calorimetry using a
computer-controlled, open circuit system (Applied Electrochemistry Inc,
Pittsburgh, Pennsylvania). Measurements were made at 10:00 on day 7.CELL METABOLISM : AUGUST 2005
Enhancing hepatic glycolysis reduces obesityAfter 1 hr to acclimate to the chamber, gases were sampled from the cham-
ber every 2 min for the remaining 4 hr. During the entire 5 hr RQ measure-
ment, food was restricted. The system then calculated the volumes of O2
consumed (VO2, ml/kg body weight) and CO2 produced (VCO2, ml/kg body
weight) by the mouse every 2 min (Baar et al., 2004; Chen and Heiman,
2001). RQ is the ratio of VCO2 to VO2. Energy expenditure is calculated as
EE = (3.185 + 1.232 × RQ) × VO2 (Chen and Heiman, 2001).
Euglycemic/hyperinsulinemic clamp studies
An infusion catheter was inserted into a jugular vein of adenovirus-treated
mice on day 5 (Rossetti et al., 1997). The clamp studies were conducted in
conscious mice on day 7 after 5 hr fasting. The procedure included an 80
min basal and a 90 min hyperinsulinemic clamp period for assessment of
the rates of glucose turnover, which were measured with prime-continuous
infusion of [3-3H]glucose (Muse et al., 2004; Rossetti and Giaccari, 1990;
Rossetti et al., 1997).
Measurement of lipogenesis
The in vivo hepatic lipogenesis of adenovirus-treated mice was measured
on day 7. Briefly, each mouse was injected intraperitoneally with 0.3 ml of
normal saline containing 0.5 mCi of [3H]water/100 g body weight. Samples
of liver (0.5 g/mouse) were collected 1 hr after injection. Livers were solubi-
lized and heated at 90°C for 5 hr in a mixture of 1.5 ml 4 M KOH and 1.5
ml of 95% ethanol. The sterols and fatty acids were isolated as previously
described (Jiang et al., 2005). The lipogenesis of virus-treated rat primary
hepatocytes was measured during the last 3 hr incubation by adding
[14C]sodium acetate (0.5 Ci/well) to incubation media (Jiang et al., 2005).
Determination of fatty acid oxidation
Fatty acid oxidation was determined in fresh tissue using palmitate oxida-
tion method as previously described (Xu et al., 2003; Yu et al., 1997). The
rates of palmitate oxidation were calculated from the sum of 14CO2 and
14C-labeled perchloric acid-soluble products.
Quantitation of mRNA by real-time PCR
The mRNA levels were measured using real-time PCR as previously de-
scribed (Wu et al., 2004). Primer sequences are available upon request.
Total RNA was isolated from frozen liver, skeletal muscle, or hypothalami
using STAT 60 reagent according to the manufacturer’s protocol (TEL-TEST
B Inc., Friendswood, Texas). Reverse transcription-PCR reactions were per-
formed using the One-Step RT-PCR kit using 250 ng of total RNA (Roche
Diagnostics Corporation, Indianapolis, Indiana). A control cDNA was used
for interplate calibration, and the variability in the initial quantities of cDNA
was normalized using ribosomal 18S RNA amplifications. Results were ob-
tained from individual mice from three different groups, each tested in tripli-
cate. Results were expressed as arbitrary units indicating relative expres-
sion normalized to 18S RNA.
Western blot, immunoprecipitation, and phospho-protein gel stain
The whole-liver lysates were used for analyses of overexpression of GK or
6PFK2/FBP2 and changes in protein amount of ChREBP, AMPK, and phos-
pho-AMPK by Western blot as previously described (Wu et al., 2004). To
analyze phospho-ChREBP, liver lysates were incubated with anti-ChREBP
antibody and protein G plus agarose. The immunoprecipitation complex
was resolved by SDS-PAGE, which was then stained with the Pro-Q phos-
pho-protein gel stain reagent (Molecular Probes, Inc., Eugene, Oregon). An-
tibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
California) and Cell Signaling Technology, Inc. (Beverly, Massachusetts).
Measurement of metabolites, transaminases, and hormones
Hepatic levels of G6P, F6P, Xu5P, and lactate were assayed from frozen liver
using methods previously described (Kauffman et al., 1969; Wu et al., 2001,
2004). Hepatic TGs were extracted and concentration determined accord-
ing to the method described by Ran et al. (2004). Plasma levels of alanine
aminotranferease (ALT) and aspartate aminotransaminase (AST) were mea-
sured using colorimetric methods (Reitman and Frankel, 1957). The assays
for concentrations of plasma insulin, leptin, glucose, TGs, and free fatty
acids were performed by following protocols provided by EIA kits (American
Laboratory Products Company, Windham, New Hampshire) and metabolic
assay kits (Sigma, St. Louis, Missouri).CELL METABOLISM : AUGUST 2005Acknowledgments
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